✦ LIBER ✦

MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations

✍ Scribed by G. R. LICHTENSTEIN; M. A. KAMM; W. J. SANDBORN; A. LYNE; R. E. JOSEPH

Book ID: 108605318
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 200 KB
Volume: 27
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2008.03688.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MMX Multi Matrix System® mesalazine for

MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials

✍ W. J. SANDBORN; M. A. KAMM; G. R. LICHTENSTEIN; A. LYNE; T. BUTLER; R. E. JOSEPH 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 566 KB

Comparison of the efficacy and safety of

Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis

✍ P. R. GIBSON; B. FIXA; B. PEKÁRKOVÁ; M. BÁTOVSKÝ; G. RADFORD-SMITH; J. TIBITANZL 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

Safety and efficacy of two dose formulat

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial

✍ P. B. MINER JR; M. K. WEDEL; S. XIA; B. F. BAKER 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

Safety and tolerability of a modified fi

Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study

✍ Vladislaw Muratov; Joachim Lundahl; Aleksandra Mandic-Havelka; Kerstin Elvin; Åk 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

## Abstract Cellsorba™ is a medical device for leukocytapheresis (LCAP) treatment of ulcerative colitis (UC). Cellsorba™ EX Global type has been developed from Cellsorba E for intended use with ACD‐A as anticoagulant. We evaluated safety and efficacy of the modified Cellsorba using ACD‐A in a pilot